[
  {
    "ts": null,
    "headline": "A Major Market Rotation Is Likely Coming",
    "summary": "A major market disruption may be imminent despite AI-driven highs. Read about which stocks I recommend investing in instead.",
    "url": "https://finnhub.io/api/news?id=b7febad88bada0d483bc4faaa0721d91be81cdc22f1a853559c9466a29b0c55d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753294271,
      "headline": "A Major Market Rotation Is Likely Coming",
      "id": 136060191,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2039568842/image_2039568842.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "A major market disruption may be imminent despite AI-driven highs. Read about which stocks I recommend investing in instead.",
      "url": "https://finnhub.io/api/news?id=b7febad88bada0d483bc4faaa0721d91be81cdc22f1a853559c9466a29b0c55d"
    }
  },
  {
    "ts": null,
    "headline": "How To Build A $100,000 Dividend Portfolio: Targeting A Yield Of 15%+ In 20 Years",
    "summary": "A globally diversified dividend portfolio can help reduce risk and provide consistent dividend income. Learn more about the Dividend Income Accelerator Portfolio.",
    "url": "https://finnhub.io/api/news?id=54f8d945bccb2210d717a67356ef4d4d50db059472278b69b28246ca061322ab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753293600,
      "headline": "How To Build A $100,000 Dividend Portfolio: Targeting A Yield Of 15%+ In 20 Years",
      "id": 136060134,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1063753064/image_1063753064.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "A globally diversified dividend portfolio can help reduce risk and provide consistent dividend income. Learn more about the Dividend Income Accelerator Portfolio.",
      "url": "https://finnhub.io/api/news?id=54f8d945bccb2210d717a67356ef4d4d50db059472278b69b28246ca061322ab"
    }
  },
  {
    "ts": null,
    "headline": "European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma.",
    "url": "https://finnhub.io/api/news?id=a4c79399ce86994c741fd65f9bc1fa0d1f57ddb9389623dcb386cd731ef9af69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753284960,
      "headline": "European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma",
      "id": 136062146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma.",
      "url": "https://finnhub.io/api/news?id=a4c79399ce86994c741fd65f9bc1fa0d1f57ddb9389623dcb386cd731ef9af69"
    }
  },
  {
    "ts": null,
    "headline": "Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?",
    "summary": "Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.",
    "url": "https://finnhub.io/api/news?id=05d231aa9423b7481458c60ee5d7fffd3456c3d5c2891baadb669993f07f7b4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282440,
      "headline": "Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?",
      "id": 136062147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.",
      "url": "https://finnhub.io/api/news?id=05d231aa9423b7481458c60ee5d7fffd3456c3d5c2891baadb669993f07f7b4b"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson: “J&J is Just Beginning Its Move”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks that Jim Cramer shed light on. Cramer was incredibly bullish on the company as he said: “Now, sometimes in this game, you do just get lucky. You’ll come across a surprise quarter that tells you everything you need to know about what can cause a big […]",
    "url": "https://finnhub.io/api/news?id=fbee885c5f56237028c4f1eaba5cdfa0d580ed36b60f9808d15187da1d190452",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282251,
      "headline": "Jim Cramer on Johnson & Johnson: “J&J is Just Beginning Its Move”",
      "id": 136062148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks that Jim Cramer shed light on. Cramer was incredibly bullish on the company as he said: “Now, sometimes in this game, you do just get lucky. You’ll come across a surprise quarter that tells you everything you need to know about what can cause a big […]",
      "url": "https://finnhub.io/api/news?id=fbee885c5f56237028c4f1eaba5cdfa0d580ed36b60f9808d15187da1d190452"
    }
  },
  {
    "ts": null,
    "headline": "QDEF: Dividend ETF With Little To Show",
    "summary": "FlexShares Quality Dividend Defensive Index Fund ETF has a portfolio of 127 dividend stocks based on a quality score and beta optimization. Read why QDEF is a Buy.",
    "url": "https://finnhub.io/api/news?id=6a3a4e23ad540f3dfa7c83a99e1e86bf5e8074bc3d76e82a0ae0d0aff4ac124a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753281748,
      "headline": "QDEF: Dividend ETF With Little To Show",
      "id": 136049720,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389129618/image_1389129618.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "FlexShares Quality Dividend Defensive Index Fund ETF has a portfolio of 127 dividend stocks based on a quality score and beta optimization. Read why QDEF is a Buy.",
      "url": "https://finnhub.io/api/news?id=6a3a4e23ad540f3dfa7c83a99e1e86bf5e8074bc3d76e82a0ae0d0aff4ac124a"
    }
  },
  {
    "ts": null,
    "headline": "Shopify and Unity downgraded: Wall Street's top analyst calls",
    "summary": "Shopify and Unity downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=0e4362922639837b3b2e7e6ddb20fdc5e4c754fd7e6b0b22fb42a137cd8c2193",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753278116,
      "headline": "Shopify and Unity downgraded: Wall Street's top analyst calls",
      "id": 136044175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Shopify and Unity downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=0e4362922639837b3b2e7e6ddb20fdc5e4c754fd7e6b0b22fb42a137cd8c2193"
    }
  },
  {
    "ts": null,
    "headline": "European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma",
    "summary": "Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring1 This milestone marks a critical advance in early intervention for multiple myeloma as the first authorised treatment, offering a new treatment paradigm for patients with high-risk smouldering disease2 Beerse, Belgium, July 23, 2025 (GLOBE NEWSWIRE) -- Ja",
    "url": "https://finnhub.io/api/news?id=26b80aae99a7e11ba7fd0569bb917e085c8f919e7cea209e1a3bb369d3d22195",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753263000,
      "headline": "European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma",
      "id": 136044176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring1 This milestone marks a critical advance in early intervention for multiple myeloma as the first authorised treatment, offering a new treatment paradigm for patients with high-risk smouldering disease2 Beerse, Belgium, July 23, 2025 (GLOBE NEWSWIRE) -- Ja",
      "url": "https://finnhub.io/api/news?id=26b80aae99a7e11ba7fd0569bb917e085c8f919e7cea209e1a3bb369d3d22195"
    }
  },
  {
    "ts": null,
    "headline": "European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant",
    "summary": "Ibrutinib is the first approved Bruton’s tyrosine kinase (BTK) inhibitor to demonstrate statistically meaningful outcomes versus autologous stem cell transplant (ASCT) for the frontline treatment of transplant eligible patients with mantle cell lymphoma1 Data from the Phase 3 TRIANGLE study defines the fixed-duration ibrutinib-based regimen as a new standard of care (SOC) with significantly improved overall survival and failure-free survival versus ASCT1 BEERSE, BELGIUM, July 23, 2025 (GLOBE NEW",
    "url": "https://finnhub.io/api/news?id=3bbc87e7e187893511490b209d1f5c745fab0fc2e6a0339c3a044da45500d489",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753261560,
      "headline": "European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant",
      "id": 136039630,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Ibrutinib is the first approved Bruton’s tyrosine kinase (BTK) inhibitor to demonstrate statistically meaningful outcomes versus autologous stem cell transplant (ASCT) for the frontline treatment of transplant eligible patients with mantle cell lymphoma1 Data from the Phase 3 TRIANGLE study defines the fixed-duration ibrutinib-based regimen as a new standard of care (SOC) with significantly improved overall survival and failure-free survival versus ASCT1 BEERSE, BELGIUM, July 23, 2025 (GLOBE NEW",
      "url": "https://finnhub.io/api/news?id=3bbc87e7e187893511490b209d1f5c745fab0fc2e6a0339c3a044da45500d489"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Pain 8 Major Market Forecast Report 2025-2034 | Opioids and Non-Opioids Drive Innovations, Medical Cannabis Emerges as Alternative",
    "summary": "The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6.10%. Growth is driven by rising cancer cases and advancements in pain management, including medical cannabis. Key players include Eli Lilly, Pfizer, and Johnson & Johnson. Cancer Pain Market Cancer Pain Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Pain Market Report and Forecast 2025-2034\" report has been added to ResearchAndMarkets.com's offering.The canc",
    "url": "https://finnhub.io/api/news?id=cd387d7651a3df8bb96f38bcdf02db1a89535f3ab4083bcf6a56127b0a5f35ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753258140,
      "headline": "Cancer Pain 8 Major Market Forecast Report 2025-2034 | Opioids and Non-Opioids Drive Innovations, Medical Cannabis Emerges as Alternative",
      "id": 136039626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6.10%. Growth is driven by rising cancer cases and advancements in pain management, including medical cannabis. Key players include Eli Lilly, Pfizer, and Johnson & Johnson. Cancer Pain Market Cancer Pain Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Pain Market Report and Forecast 2025-2034\" report has been added to ResearchAndMarkets.com's offering.The canc",
      "url": "https://finnhub.io/api/news?id=cd387d7651a3df8bb96f38bcdf02db1a89535f3ab4083bcf6a56127b0a5f35ba"
    }
  },
  {
    "ts": null,
    "headline": "Ipsen announces changes to its Executive Committee",
    "summary": "PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product OfficerAndreas Gerber is appointed to EVP, Head of InternationalCaroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading",
    "url": "https://finnhub.io/api/news?id=24660e436dcf68c88cd80fc016205c85240e25e68b5c497b2ab9a164b82bac72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753248600,
      "headline": "Ipsen announces changes to its Executive Committee",
      "id": 136038214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product OfficerAndreas Gerber is appointed to EVP, Head of InternationalCaroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading",
      "url": "https://finnhub.io/api/news?id=24660e436dcf68c88cd80fc016205c85240e25e68b5c497b2ab9a164b82bac72"
    }
  }
]